Atypical Hemolytic Uremic Syndrome (aHUS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report

Atypical Hemolytic Uremic Syndrome (aHUS) is a rare genetic thrombotic microangiopathy. It results from the dysregulation of the alternative complement pathway and is characterized by hemolytic anemia, thrombocytopenia, and acute renal dysfunction. Most cases involve uncontrolled complement activation, damaging endothelial cells. Pathogenic mutations occur in genes related to complement regulation, including CFH, CFI, CD46, C3, and CFB, along with rearrangements in CFH and related genes. Symptoms can manifest at any age, typically appearing suddenly with microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure triggered by respiratory infections or gastroenteritis. In some cases, onset is gradual with recurrent subclinical symptoms like anemia and thrombocytopenia, along with vague symptoms like fatigue and loss of appetite. Roughly half of patients progress to end-stage kidney disease. Diagnosis relies on genetic testing, functional complement protein tests, and screening for factor H auto-antibodies. Tests should assess various complement factors and look for copy number variations in CFHR genes and their hybrids with CFH. Differential diagnoses include HUS due to Shiga toxin-producing E. coli, thrombotic thrombocytopenic purpura, and HUS secondary to immunological or external factors, such as drugs. Cobalamin C deficiency can have similar presentations. The recommended first-line treatment is eculizumab, which blocks the complement terminal pathway, preventing endothelial damage and thrombotic microangiopathy.
• The incidence of Atypical hemolytic uremic syndrome (aHUS) ranges from 1 to 3 cases per 500,000 population in the USA.

Thelansis’s “Atypical Hemolytic Uremic Syndrome (aHUS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Atypical Hemolytic Uremic Syndrome (aHUS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Atypical Hemolytic Uremic Syndrome (aHUS) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Atypical Hemolytic Uremic Syndrome (aHUS) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Read more: Atypical Hemolytic Uremic Syndrome (aHUS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Tags: Atypical Hemolytic Uremic Syndrome (aHUS), Atypical Hemolytic Uremic Syndrome (aHUS) market outlook, Atypical Hemolytic Uremic Syndrome (aHUS) competitive landscape, Atypical Hemolytic Uremic Syndrome (aHUS) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)